CN1634195A - Eye disease treating medicine - Google Patents
Eye disease treating medicine Download PDFInfo
- Publication number
- CN1634195A CN1634195A CN 200310121654 CN200310121654A CN1634195A CN 1634195 A CN1634195 A CN 1634195A CN 200310121654 CN200310121654 CN 200310121654 CN 200310121654 A CN200310121654 A CN 200310121654A CN 1634195 A CN1634195 A CN 1634195A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- rhizoma
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000030533 eye disease Diseases 0.000 title claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 241000405414 Rehmannia Species 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 241000411851 herbal medicine Species 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 claims description 3
- 235000005903 Dioscorea Nutrition 0.000 claims description 2
- 241000234273 Dioscorea Species 0.000 claims description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 235000004879 dioscorea Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000004438 eyesight Effects 0.000 description 12
- 208000034700 Vitreous opacities Diseases 0.000 description 11
- 208000001749 optic atrophy Diseases 0.000 description 11
- 238000011084 recovery Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010008795 Chromatopsia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- UOZDOLIXBYLRAC-UHFFFAOYSA-L [2-hydroxy-3-(trimethylazaniumyl)propyl]-trimethylazanium;diiodide Chemical compound [I-].[I-].C[N+](C)(C)CC(O)C[N+](C)(C)C UOZDOLIXBYLRAC-UHFFFAOYSA-L 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229950002100 prolonium iodide Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
The invention relates to an eye disease treating medicine, which is prepare from fifteen Chinese medicinal herbs including Chinese angelica root, root of herbaceous peony, Poria cocos, white atractylodes rhizome, root of red rooted saliva, Bupleurum root, prepared rhizome of rehmannia, Chinese yam through boiling, concentrating, palletizing, drying, sterilizing and packaging.
Description
Technical field: the present invention relates to a kind of medicine for the treatment of disease of eye, " the compound light granule " of ophthalmic diseasess such as a kind of specifically therapeutic community's property serosity venation retinopathy, vitreous opacity, optic atrophy.
Background technology: ophthalmic diseasess such as therapeutic community's property serosity venation retinopathy, vitreous opacity, optic atrophy at present, doctor trained in Western medicine does not still have the good curing method, the concrete method that adopts is western medical treatment central serous chorioretinopathy and the oral lecithin chelated iodine of vitreous opacity, the intramuscular injection prolonium iodide.The treatment optic atrophy adopts vitamins and angiectatic medicine etc., but above-mentioned Therapeutic Method can only play mitigation, cures the symptoms, not the disease, and also there is the problem of the one-sidedness aspect of treatment in other dosage forms of the traditional Chinese medical science.
Summary of the invention: the objective of the invention is in order to overcome the deficiencies in the prior art, provide a kind of can therapeutic community's property serosity venation retinopathy, the Chinese medicine of ophthalmic diseases such as vitreous opacity, optic atrophy.
In order to achieve the above object, technical scheme of the present invention is:
Medicine of the present invention is made (consumption is a weight portion) by following component
Radix Angelicae Sinensis 10-13 part Radix Paeoniae Alba 14-18 part Poria 18-22 part
Rhizoma Atractylodis Macrocephalae 23-27 part Radix Salviae Miltiorrhizae 11-13 part Radix Bupleuri 18-22 part
Radix Rehmanniae Preparata 18-22 part Rhizoma Dioscoreae 14-18 part Radix Rehmanniae 18-22 part
Fructus Lycii 23-27 part Magnetitum 14-18 part Fructus Gardeniae 10-13 part
Rhizoma Cimicifugae 10-12 part Fructus Schisandrae Chinensis 10-13 part Radix Glycyrrhizae 6-10 part
Medicine optimum weight proportioning of the present invention is:
25 parts of 20 parts of Rhizoma Atractylodis Macrocephalaes of 16 parts of Poria of 12 portions of Radix Paeoniae Albas of Radix Angelicae Sinensis
16 parts of 20 portions of Rhizoma Dioscoreaes of 20 parts of Radix Rehmanniaes Preparata of 12 parts of Radix Bupleuri of Radix Salviae Miltiorrhizae
12 parts of 16 parts of Fructus Gardeniae of 25 parts of Magnetitums of 20 parts of Fructus Lycii of the Radix Rehmanniae
8 parts in 12 portions of Radix Glycyrrhizaes of 12 parts of Fructus Schisandrae Chinensis of Rhizoma Cimicifugae
The method of above-mentioned each component being made medicine of the present invention is: above-mentioned ten five tastes Chinese herbal medicine are added decocting firmly boil three times; 2 hours for the first time; 2 hours for the second time, one hour for the third time, gradation filtered; merging filtrate; static 24 hours, getting supernatant concentration to relative density was 1.35-1.38, and it is an amount of to add cane sugar powder, purified water, ethanol; make granule by granulator, final drying, sterilization, packing promptly get product of the present invention.
The dosage form of product of the present invention is a granule, and character is a dark brown granule, and it is sweet to distinguish the flavor of, little acid, and packing specification is the 10g/ bag, instructions of taking is that boiled water is taken after mixing it with water, each 1 bag, three times on the one.
The effect that medicine of the present invention has nourishing kidney, nourishing the liver, the wind that looses makes eye bright has notable therapeutic effect to ophthalmic diseasess such as central serous chorioretinopathy, vitreous opacity, optic atrophys.
Clinical therapeutic efficacy:
Oculopathy such as central serous chorioretinopathy (this title abbreviates middle slurry as later on), vitreous opacity, optic atrophy, the category of genus motherland's medical science " blurring of vission ", " chromatopsia ", " optic atrohic blindness ".The cause of disease is because hepatic and renal YIN deficiency, the essence and blood consume, can not on hold, order loses due to the self-restraint.
The inventor through clinical observation in 8 years, through contrasting and statistical procedures with matched group, proves that it is evident in efficacy with above-mentioned sufferer 300 examples of Chinese medicine compound light granule therapy.Now clinical research is reported as follows:
1, clinical data: middle slurry, vitreous opacity, each 100 example (100 eyes) of optic atrophy patient are made a definite diagnosis in outpatient service, the men and women does not have significant difference, age 20---70 year, average 45 years old, every kind of disease is divided into two groups at random, compound light granule therapy group (every kind of each 50 example of disease), matched group (every kind of each 50 example of disease) uses western medicine, middle slurry, the oral lecithin chelated iodine of vitreous opacity, the intramuscular injection prolonium iodide, optic atrophy is with vitamin medicaments, as vitamin B1, vitamin B12, vasodilation treatment.
2, Therapeutic Method: the particulate main component of compound light is 15 flavor Chinese medicines such as Radix Angelicae Sinensis, white peony root, Poria, the Rhizoma Atractylodis Macrocephalae, Radix Salviae Miltiorrhizae, Radix Bupleuri, Radix Rehmanniae Preparata, Rhizoma Dioscoreae, the Radix Rehmanniae, Fructus Lycii, Magnetitum, and above-mentioned 15 flavor Chinese medicines are decocted with water two hours for the first time 3 times, two hours for the second time, one hour for the third time, gradation filtered, merging filtrate, static 24 hours, getting supernatant concentration to relative density was 1.35-1.38, adds cane sugar powder, purified water, ethanol is an amount of, makes particle drying, makes 1500 grams, promptly.Each 10 grams, every day 3 times, oral.10 days was 1 course of treatment, and 1-2 observes therapeutic effect the course of treatment, and the observation period is limited to 3 months.
3, observational technique, index and curative effect judging standard: observe indexs such as suffering from eye symptom, sign weekly, curative effect is divided into recovery from illness, produce effects, effective, invalid level Four.Recovery from illness with effectively add up to effectively, be the raising standard of testing eyesight with standard logarithmic visual acuity chart, middle slurry reverts to recovery from illness to recover original vision central fovea of macula luminous reflectance.Improve 3 row with vision, hydrops obviously is absorbed as produce effects under the nethike embrane, improves 1 row with vision, and hydrops obviously is absorbed as effectively under the nethike embrane, vision and optical fundus do not have change into invalid.Vitreous opacity disappears with subjective symptoms, ophthalmoscopy, the eye ultrasound diagnosis is asymptomatic for fully recovering, with subjective symptoms be clearly better, examination of ocular fundus, all to be clearly better be produce effects in an eye ultrasound diagnosis, take a turn for the better with subjective symptoms, ophthalmoscopy, the eye ultrasound diagnosis slightly transfers to well effectively, is invalid with the subjective symptoms no change.Optic atrophy is looked the nipple color and luster and is reverted to recovery from illness to recover original vision, improves 3 row with vision, looks the nipple color and luster and obviously reverts to produce effects, improves 1 row with vision, looks the nipple color and luster and obviously reverts to effectively, with vision and to look nipple color and luster no change be invalid.
4, result
Curative effect is examined and be the results are shown in Table 1,2,3:
Table 1, middle slurry observed result:
| Group | The eye number | Recovery from illness | Produce effects | Effectively | Invalid | Cure rate | Effective percentage |
| The treatment group | 50 | 48 | 2 | 0 | 0 | 96％ | 100％ |
| Matched group | 50 | 30 | 10 | 5 | 5 | 60％ | 90％ |
Table 2, vitreous opacity observed result:
| Group | The eye number | Recovery from illness | Produce effects | Effectively | Invalid | Cure rate | Effective percentage |
| The treatment group | 50 | 41 | 5 | 4 | 0 | 82％ | 100％ |
| Matched group | 50 | 15 | 4 | 3 | 28 | 30％ | 44％ |
Table 3, optic atrophy observed result:
| Group | The eye number | Recovery from illness | Produce effects | Effectively | Invalid | Cure rate | Effective percentage |
| The treatment group | 50 | 20 | 21 | 5 | 4 | 40％ | 92％ |
| Matched group | 50 | 2 | 8 | 5 | 35 | 4％ | 30％ |
From table 1,2,3 as can be seen, treatment group and matched group exist significant difference, and compound light granule therapy produce effects is fast, curative effect is good, are better than simple western modern medicine treatment.
5, model case
Wang Qingfei, man, 50 years old.Guo Jia people from shop, Lishu County.On March 8th, 1999 examined.Conscious right eye metamorphopsia, diminish, muscae genetic vision, surplus the visual deterioration 10 day.Vision: the right side 4.3, a left side 5.0, the shallow disengaging of the big patelliform slurry retina of the visible 3PD of macular area at the bottom of the right eye has reflective swooning on every side, and the central fovea luminous reflectance disappears, and fluorescence fundus angiography is diagnosed as middle slurry, and the primary disease course of disease was generally 3---6 month.It is oral to give compound granular, each 10 grams, and every day 3 times, after 20 days, patient's subjective symptoms disappears, vision restoration 5.0, it is normal that recover on the optical fundus, continues with 10 days, as a means of consolidation.
Zhang Wei, man, 39 years old.Guo Jia people from shop, Lishu County, on January 8th, 2000 examined.Shadow is waved before the conscious left eye, blurring of vision half a year.Vision: the right side 5.0, a left side 4.8, several unsetting canescence dregs in the visible vitreous body in optical fundus, an eye ultrasound diagnosis is diagnosed as vitreous opacity.Give the compound light particulate oral, each 10 grams, every day 3 times, after 2 months, patient's subjective symptoms disappears, vision restoration 5.0, ophthalmoscopy, eye ultrasound diagnosis transference cure continues with 10 days, as a means of consolidation.
Li Guirong, woman, 52 years old.The retired cadre, JIUYUE was examined on the 3rd in 1998.Conscious right eye blurring of vision 2 years.Vision: the right side 4.5, a left side 5.0, it is pale that the examination of ocular fundus right eye is looked nipple temporo side color, and the border is clear, retinal vessel normally gives the compound light particulate oral, each 10 grams, and every day 3 times is after 2 months, look the nipple color and luster and recover substantially, vision restoration 5.0 continues with 10 days, as a means of consolidation.
6, discuss
Oculopathy such as middle slurry, vitreous opacity, optic atrophy, the category of genus motherland's medical science " blurring of vission ", " chromatopsia ", " optic atrohic blindness ".How by hepatic and renal YIN deficiency, the essence and blood consume, can not on hold, order loses self-restraint.Insufficiency of kidney-YANG, decline of the fire from the gate of life, vital essence can not sending nutrient upward to eye.Eating and drinking without temperance or impairment caused by overstrain are excessive, and temper is impaired, can not transport to be skillful in order.Seven emotions pent-up, wood are lost bar and are reached, the heart-nutriment loss, the empty consumption of manner, so that eyes being lustreless and spiritless.
" optic atrohic blindness ", blurring of vission ", " chromatopsia " all belong to chronic disease, with the passing of time back two kinds of card marquis are not healed; become the optic atrohic blindness serious symptom; its common feature is that vision and vision change, but are not had the sign of pupil god's distortion and variable color, the conscious vision of optic atrohic blindness person fades, blind at last.The blurring of vission person, the outer observation of eye do not have his disease, and it is conscious that to look thing dusk vast, uncivilized unclear, and chromatopsia person, pupil manner color are normal, shade a slice but the patient has considered oneself as, even present blue green color of a sheet of viridescent or helvolus at the moment.Though more than three diseases on symptom to some extent the difference, because of pathogenesis identical.So method of treatment is identical.Control suitable enriching yin and nourishing kidney, the gentle wood of nourishing the liver, warming and recuperating the kidney-YANG, tonifying Qi and lifting yang.Radix Rehmanniae Preparata, Rhizoma Dioscoreae, Fructus Lycii the kidney invigorating and essence nourishing in the side, the training tonifying kidney-yin.The Fructus Gardeniae clearing away heat-damp and promoting diuresis.Radix Angelicae Sinensis, the Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae invigorating the spleen and benefiting QI.The Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI, yang invigorating, the vital essence sending nutrient upward to eye of act Liver and kidney.Radix Salviae Miltiorrhizae has that diffusing heavily fortified point is invigorated blood circulation, the effect of blood stasis dispelling.The Poria promoting diuresis to eliminate damp pathogen.Radix Rehmanniae nourishing the liver and kidney.The Fructus Schisandrae Chinensis nourishing the liver to improve visual acuity.Rhizoma Cimicifugae detoxifcation yang invigorating.Magnetitum improving inspiration by invigorating kidney-QI YANG hyperactivity suppressing.All medicines share, and Baconic consolidates, strengthening body resistance and dispelling evil.Dispersing the stagnated live-QI to relieve the stagnation of QI is arranged, regulating functional activities of qi, the effect of liver and kidney tonifying.Treating both the principal and secondary aspects of a disease, just middle pathogenesis, all disease spontaneous recovery.
Embodiment:
Take by weighing Radix Angelicae Sinensis 120g by proportion of raw materials; Radix Paeoniae Alba 160g; Poria 200g; Rhizoma Atractylodis Macrocephalae 250g; Radix Salviae Miltiorrhizae 120g; Radix Bupleuri 200g; Radix Rehmanniae Preparata 200g; Rhizoma Dioscoreae 160g; Radix Rehmanniae 200g; Fructus Lycii 250g; Magnetitum 160g; Fructus Gardeniae 120g; Rhizoma Cimicifugae 120g; Fructus Schisandrae Chinensis 120g; Radix Glycyrrhizae 80g; above-mentioned ten five tastes Chinese herbal medicine are added decocting firmly to be boiled three times; 2 hours for the first time; 2 hours for the second time; one hour for the third time; gradation filters; merging filtrate; static 24 hours; getting supernatant concentration to relative density is 1.35-1.38; add cane sugar powder; purified water; ethanol is an amount of; make granule by granulator; final drying; sterilization; make 1500g medicinal granule of the present invention, be packaged into the pouch that specification is the 10g/ bag at last.
Claims (2)
1, a kind of medicine for the treatment of oculopathy is characterized in that: it is the granule of being made by following materials of weight proportions:
Radix Angelicae Sinensis 10-13 part Radix Paeoniae Alba 14-18 part Poria 18-22 part
Rhizoma Atractylodis Macrocephalae 23-27 part Radix Salviae Miltiorrhizae 11-13 part Radix Bupleuri 18-22 part
Radix Rehmanniae Preparata 18-22 part Rhizoma Dioscoreae 14-18 part Radix Rehmanniae 18-22 part
Fructus Lycii 23-27 part Magnetitum 14-18 part Fructus Gardeniae 10-13 part
Rhizoma Cimicifugae 10-12 part Fructus Schisandrae Chinensis 10-13 part Radix Glycyrrhizae 6-10 part
Preparation method is: the method for above-mentioned each component being made medicine of the present invention is: above-mentioned ten five tastes Chinese herbal medicine are added decocting firmly boil three times; 2 hours for the first time; 2 hours for the second time, one hour for the third time, gradation filtered; merging filtrate; static 24 hours, getting supernatant concentration to relative density was 1.35-1.38, and it is an amount of to add cane sugar powder, purified water, ethanol; make granule by granulator, final drying, sterilization, packing promptly get product of the present invention.
2, a kind of medicine for the treatment of oculopathy according to claim 1, it is characterized in that: the weight proportion of this medicine is:
25 parts of 20 parts of Rhizoma Atractylodis Macrocephalaes of 16 parts of Poria of 12 portions of Radix Paeoniae Albas of Radix Angelicae Sinensis
16 parts of 20 portions of Rhizoma Dioscoreaes of 20 parts of Radix Rehmanniaes Preparata of 12 parts of Radix Bupleuri of Radix Salviae Miltiorrhizae
12 parts of 16 parts of Fructus Gardeniae of 25 parts of Magnetitums of 20 parts of Fructus Lycii of the Radix Rehmanniae
8 parts in 12 portions of Radix Glycyrrhizaes of 12 parts of Fructus Schisandrae Chinensis of Rhizoma Cimicifugae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310121654 CN1256128C (en) | 2003-12-30 | 2003-12-30 | Eye disease treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310121654 CN1256128C (en) | 2003-12-30 | 2003-12-30 | Eye disease treating medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634195A true CN1634195A (en) | 2005-07-06 |
| CN1256128C CN1256128C (en) | 2006-05-17 |
Family
ID=34844238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310121654 Expired - Lifetime CN1256128C (en) | 2003-12-30 | 2003-12-30 | Eye disease treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256128C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178815A (en) * | 2011-04-10 | 2011-09-14 | 刘永华 | Traditional Chinese medicine for treating ischemic optic neuropathy |
| CN102641431A (en) * | 2012-05-21 | 2012-08-22 | 修方伟 | Medicament for treating vitreous opacity |
| CN103623128A (en) * | 2013-12-12 | 2014-03-12 | 苏振华 | Medicine for treating optic atrophy and preparation method thereof |
| CN103830497A (en) * | 2014-03-12 | 2014-06-04 | 逄增容 | Traditional Chinese medicine for treating vitreous opacity and preparation method thereof |
| CN104043045A (en) * | 2014-06-20 | 2014-09-17 | 张铭连 | Pharmaceutical composition for treating optic atrophy |
| CN106668237A (en) * | 2016-08-25 | 2017-05-17 | 吴斌 | Medicine for treating optic atrophy |
-
2003
- 2003-12-30 CN CN 200310121654 patent/CN1256128C/en not_active Expired - Lifetime
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178815A (en) * | 2011-04-10 | 2011-09-14 | 刘永华 | Traditional Chinese medicine for treating ischemic optic neuropathy |
| CN102178815B (en) * | 2011-04-10 | 2012-03-21 | 刘永华 | Traditional Chinese medicine for treating ischemic optic neuropathy |
| CN102641431A (en) * | 2012-05-21 | 2012-08-22 | 修方伟 | Medicament for treating vitreous opacity |
| CN102641431B (en) * | 2012-05-21 | 2013-07-10 | 修方伟 | Medicament for treating vitreous opacity |
| CN103623128A (en) * | 2013-12-12 | 2014-03-12 | 苏振华 | Medicine for treating optic atrophy and preparation method thereof |
| CN103623128B (en) * | 2013-12-12 | 2015-07-08 | 苏振华 | Medicine for treating optic atrophy and preparation method thereof |
| CN103830497A (en) * | 2014-03-12 | 2014-06-04 | 逄增容 | Traditional Chinese medicine for treating vitreous opacity and preparation method thereof |
| CN104043045A (en) * | 2014-06-20 | 2014-09-17 | 张铭连 | Pharmaceutical composition for treating optic atrophy |
| CN106668237A (en) * | 2016-08-25 | 2017-05-17 | 吴斌 | Medicine for treating optic atrophy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1256128C (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1066945C (en) | Chinese drug Mingmudan pill for improving eyesight and its producing method | |
| CN1256128C (en) | Eye disease treating medicine | |
| CN101390993A (en) | Traditional Chinese medicine for treating diabetic foot | |
| CN1323595A (en) | Composite medicine for glaucoma | |
| CN101843837B (en) | Chinese medicament for treating diabetic oculopathy | |
| CN101884693B (en) | Traditional Chinese medicine for treating diabetic eye diseases | |
| CN110339314A (en) | A kind of eyesight patch and preparation method thereof | |
| CN101843786A (en) | Chinese medicament for treating diabetic eyeground pathological changes | |
| CN1278723C (en) | Chinese medicine prescription for breating diabetes retina pathologic change | |
| CN103536880B (en) | A kind of Chinese medicine for the treatment of type 2 diabetes mellitus peripheral neuropathy | |
| CN115444903A (en) | Application of rehabilitation eyesight oral liquid in preparation of eyesight improving medicine | |
| CN101391071B (en) | Traditional Chinese medicine for treating diabetic ocular fundus diseases | |
| CN101966258A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN104623282A (en) | Traditional Chinese medicine healthy preparation for conditioning hypertension | |
| CN101843834B (en) | Chinese medicament for treating diabetic eyeground pathological changes | |
| CN101843857B (en) | Chinese medicament for treating diabetic eyeground pathological changes | |
| CN101843772A (en) | Chinese medicament for treating diabetic oculopathy | |
| CN101953938A (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN101940659A (en) | Traditional Chinese medicine for treating diabetic eye disease | |
| CN102018757A (en) | Traditional Chinese medicine for treating eyeground pathological changes caused by diabetes | |
| CN109105732A (en) | A kind of alleviation visual fatigue rice paste and preparation method thereof | |
| CN101953939A (en) | Chinese medicament for treating diabetic eye diseases | |
| CN109464589A (en) | A kind of blood-enriching soup and preparation method thereof | |
| CN101843788A (en) | Chinese medicament for treating diabetic oculopathy | |
| CN101843770A (en) | Chinese medicament for treating diabetic oculopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG WENLONG Free format text: FORMER OWNER: SECOND-WING MILITARY REHABILITATION HOSPITAL,JILIN PROVINCE Effective date: 20080704 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080704 Address after: A group of Rong County Committee, Guo Zhen Town, Lishu County, Jilin Patentee after: Zhang Wenlong Address before: Guo Zhen Town, Lishu County, Jilin Patentee before: The Second Rongfu Military Hospital In Jilin |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160425 Address after: 730000, No. 2299, Middle Road, Dunhuang Road, Lanzhou New District, Gansu Province, No. thirteen Patentee after: Lanzhou Heshengtang Pharmaceutical Co.,Ltd. Address before: 136502, Jilin province Lishu County Guo Zhen Zhen Rong Committee a group Patentee before: Zhang Wenlong |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 730000 Gansu, Lanzhou, New District, Kunlun Mountains Avenue, No. 2299, No. Patentee after: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Address before: 730000, No. 2299, Middle Road, Dunhuang Road, Lanzhou New District, Gansu Province, No. thirteen Patentee before: Lanzhou Heshengtang Pharmaceutical Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition for eye diseases Effective date of registration: 20170301 Granted publication date: 20060517 Pledgee: Lanzhou New District Klc Holdings Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Registration number: 2017620000004 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191231 Granted publication date: 20060517 Pledgee: Lanzhou New District Klc Holdings Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Registration number: 2017620000004 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition for eye diseases Effective date of registration: 20200107 Granted publication date: 20060517 Pledgee: Lanzhou New District Klc Holdings Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Registration number: Y2020620000001 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210105 Granted publication date: 20060517 Pledgee: Lanzhou New District Klc Holdings Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020620000001 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for eye diseases Effective date of registration: 20210205 Granted publication date: 20060517 Pledgee: Lanzhou new area science and Technology Culture Tourism Group Co.,Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021620000004 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220302 Granted publication date: 20060517 Pledgee: Lanzhou new area science and Technology Culture Tourism Group Co.,Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Registration number: Y2021620000004 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060517 |